EPS Holdings, Inc. (HQ : Tokyo Japan, Hao Yan, Representative Director, “EPS" hereafter) has announced today that EPS International Co., Ltd.(HQ : Shanghai China, Ping Yan, Chairman, “Ekishin" hereafter) of EPS Group companies has reached an Equity Transfer Agreement on the acquisition of Beijing Global Pharmaceutical Research Co., Ltd. (HQ : Beijing China, Bing Hao, Executive Director; “G&P” hereafter) in order to provide CRO services and pharmaceutical consulting in China.

The large Chinese medical and pharmaceutical products market (second in size only to the US market) is expected to continue to grow rapidly with an initiative announced by local authorities to reform its review and approval systems. Service providers who offer comprehensive support in developing medical and pharmaceutical products will play an increasingly important role. It is especially valuable to have such a total service provider having expertise in pharmaceutical regulatory strategy.

G&P employees, many of whom worked for local Chinese subsidiaries of Japanese pharmaceutical companies, are well versed in planning medical and pharmaceutical product development and in regulatory submission and registration of pharmaceuticals. The strong relationships they have built with local authorities serve as a definite strength in the market.

The EPS Group entered the Chinese market in 2001 as one of first Japanese CROs to do so. Since then, EPS Group has provided customers with a wide range of services. This acquisition will make EPS capable to provide even more advanced services to customers in Japan and overseas.

EPS will continue to focus on creating new services under the corporate philosophy of the EPS Group: "We will contribute to the advancement of the healthcare industry by providing high-value- added solutions to our clients. "

Outline of G&P
1) Registered trade name: Beijing Global Pharmaceutical Research Co., Ltd.
2) Address of Headquarters: No.4 Building 903-904, Guancheng Midtown Plaza, Dong Cheng District, Beijing, China
3) Representative: Bing Hao, Executive Director
4) Business description: Clinical Trial Services, Technical Promotion Services, Technical Training Services of food safety
5) Capital: 500,000 RMB
6) Employees: 28

[About EPS Group]
Since its establishment in 1991 as one of the pioneering CROs covering Asia, EPS Group has been a Healthcare Solution Provider to Pharmaceutical companies, Medical device manufacturers, Hospitals, Clinics, and Academia with various solutions from Clinical Development to Marketing, Sales, Consultation and new values created in big data & AI, regenerative medicine, etc.
https://www.eps-holdings.co.jp/en/

[Contacts]
Tsumoru Miyano
Investment Strategy
EPS Holdings, Inc.
E-mail: miyano835@eps.co.jp

日本語版PDFはこちら